Optima Health's £100m acquisition will help it scale; brokers call PAM deal defensive and earnings-enhancing

Core Viewpoint - Optima Health's acquisition of PAM Healthcare for approximately £100 million is seen as a strategic move to enhance its market position in the UK outsourced occupational health sector, aiming for a dominant market share and improved financial performance [1][2][3]. Market Position and Growth - The acquisition will increase Optima's pro forma market share to about 15% in the £1.6 billion UK and Republic of Ireland occupational health market, positioning it as a clear market leader [2][3]. - This deal is expected to significantly accelerate Optima's revenue target of £200 million and adjusted EBITDA target of £40 million in the medium term [2]. Valuation and Financial Impact - The acquisition is valued at approximately 12.2 times historic adjusted EBITDA, with a forward multiple of about 9.6 times, which is slightly below Optima's own trading multiple [4]. - Following the acquisition, Cavendish has revised its adjusted EBITDA forecasts for the years ending March 2027 and March 2028, increasing expectations to £28.2 million from £19.6 million and £34.4 million from £22.4 million, respectively [6]. Financing Structure - Optima plans to finance the acquisition through £70 million in new bank facilities and a £30 million bridge loan from Deacon Street Partners, its largest shareholder [5]. - An open offer of £35 million will be launched at a price of 175p to repay the bridge loan and cover associated costs, allowing for quick cash payment without the risk of a placing [6]. Future Projections - The combination of Optima and PAM Healthcare is expected to generate significant economies of scale, supporting margin improvement over time [7]. - Target prices have been set at 271p by Cavendish and 225p by Panmure, with a pro forma value of 250p anticipated once the deal and open offer are finalized [7]. Current Stock Performance - As of early afternoon trading, Optima's stock was priced at 209.9p [8].